Cryo-Cell International, Inc. (CCEL) Income Statement
CCEL FY2025 at a glance
Fiscal year ended November 30, 2025 · U.S. dollarsCCEL revenue and net income
Where CCEL's revenue goes
FY2025Each bar shows an amount and its share of revenue. CCEL kept −7.7% of revenue as net income.
CCEL profit margins
CCEL growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −1.3% | +1.3% | +0.3% | +4.1% |
| Gross profit | +0.6% | +3.9% | +2.4% | +4.6% |
| Operating income | +39.1% | +6.4% | −8.8% | +5.1% |
| Net income | −704.2% | — | — | — |
| EPS (diluted) | −437.5% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CCEL quarterly EPS vs estimates
Cryo-Cell International beat the analyst EPS estimate in 5 of the last 7 quarters.
CCEL income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M | $31.1M | $31.8M | $29.2M | $25.4M | $23.1M |
| Cost of revenue | $7.4M | $7.9M | $8.4M | $8.8M | $9.0M | $9.7M | $10.0M | $8.5M | $6.7M | $5.8M |
| Gross profit | $24.2M | $24.0M | $22.9M | $21.5M | $19.9M | $21.5M | $21.8M | $20.7M | $18.7M | $17.4M |
| Research & development | $376,263 | $1.2M | $1.2M | $384,789 | $49,870 | $23,851 | $30,145 | $91,845 | $41,165 | $53,097 |
| Sales, general & admin | $18.2M | $18.5M | $17.1M | $15.6M | $14.6M | $14.3M | $14.9M | $15.6M | $13.5M | $14.7M |
| Total operating expenses | $19.3M | $20.6M | $35.2M | $17.5M | $15.9M | $13.8M | $16.7M | $15.5M | $13.7M | $16.9M |
| Operating income | $4.8M | $3.5M | −$12.3M | $4.0M | $4.0M | $7.7M | $5.1M | $5.2M | $5.0M | $433,594 |
| Interest expense | $2.1M | $1.9M | $1.2M | $1.5M | $1.4M | $1.5M | $1.7M | $1.5M | $1.3M | $947,340 |
| Income before taxes | −$2.3M | $2.8M | −$13.4M | $3.3M | $2.6M | $5.0M | $3.4M | $3.6M | $3.6M | −$2.5M |
| Income taxes | $92,232 | $2.4M | −$3.8M | $547,540 | $527,710 | $1.4M | $1.1M | $4.5M | $1.3M | −$1.2M |
| Net income | −$2.4M | $402,095 | −$9.5M | $2.8M | $2.1M | $3.6M | $2.3M | −$854,824 | $2.3M | −$1.3M |
| EBITDA | $1.1M | $2.0M | −$10.4M | $6.7M | $5.3M | $7.2M | $5.5M | $5.5M | $5.2M | −$1.2M |
| EPS (diluted) | −$0.27 | $0.08 | −$1.15 | $0.33 | $0.25 | $0.45 | −$0.69 | −$0.10 | $0.69 | −$0.09 |
| Gross margin | 76.6% | 75.2% | 73.1% | 71.0% | 68.9% | 69.0% | 68.5% | 70.8% | 73.5% | 75.0% |
| Operating margin | 15.3% | 10.9% | −39.3% | 13.3% | 13.9% | 24.6% | 15.9% | 17.8% | 19.7% | 1.9% |
| Net margin | −7.7% | 1.3% | −30.4% | 9.1% | 7.2% | 11.6% | 7.2% | −2.9% | 9.1% | −5.7% |
| Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $7.8M | $7.7M | $7.8M | $7.8M | $7.9M | $8.0M | $8.0M | $8.1M | $8.0M | $7.9M | $7.9M |
| Cost of revenue | $1.6M | $1.9M | $1.7M | $1.7M | $1.8M | $1.9M | $2.0M | $1.6M | $2.1M | $2.0M | $2.1M | $2.1M |
| Gross profit | $6.2M | $5.9M | $6.0M | $6.1M | $6.0M | $6.1M | $6.0M | $6.4M | $5.9M | $6.0M | $5.8M | $5.8M |
| Research & development | $53,624 | $99,781 | $65,761 | $84,784 | $61,625 | $131,711 | $98,143 | $304,629 | $193,933 | $241,085 | $502,889 | $443,808 |
| Sales, general & admin | — | $4.6M | $5.0M | $4.3M | — | $4.3M | $4.6M | $6.0M | $4.1M | $4.0M | $4.3M | $5.4M |
| Total operating expenses | $4.0M | $4.7M | $5.3M | $10.1M | $4.1M | $4.6M | $4.9M | $6.5M | $4.6M | $4.6M | $5.0M | $22.0M |
| Operating income | $2.2M | $1.2M | $765,134 | −$4.0M | $1.9M | $1.5M | $1.1M | −$122,347 | $1.4M | $1.4M | $821,223 | −$16.2M |
| Interest expense | $438,305 | $441,917 | $462,709 | $481,949 | $538,219 | $551,126 | $494,962 | $745,488 | $533,464 | $329,273 | $256,459 | $169,031 |
| Income before taxes | $1.8M | $827,781 | $70,309 | −$4.6M | $1.2M | $575,103 | $533,718 | −$842,434 | $1.4M | $1.5M | $794,510 | −$16.0M |
| Income taxes | $554,958 | $273,195 | $23,201 | $58,639 | −$436,588 | $219,318 | $250,863 | $1.0M | $328,186 | $816,390 | $238,269 | −$4.8M |
| Net income | $1.3M | $554,586 | $47,108 | −$4.7M | $1.6M | $355,785 | $282,855 | −$1.9M | $1.1M | $655,790 | $556,241 | −$11.2M |
| EBITDA | $2.5M | $1.6M | $875,017 | −$3.8M | $2.1M | $1.5M | $1.4M | $242,502 | −$1.5M | $2.0M | $1.2M | −$15.8M |
| EPS (diluted) | $0.16 | $0.07 | $0.02 | −$0.47 | $0.10 | $0.05 | $0.05 | −$0.25 | $0.14 | $0.10 | $0.09 | −$1.34 |
| Gross margin | 79.4% | 76.1% | 78.4% | 77.9% | 77.0% | 76.6% | 75.1% | 79.6% | 73.6% | 74.8% | 73.7% | 73.6% |
| Operating margin | 28.0% | 15.4% | 10.0% | −50.6% | 24.3% | 18.8% | 13.3% | −1.5% | 17.2% | 17.3% | 10.5% | −205.4% |
| Net margin | 16.2% | 7.1% | 0.6% | −59.8% | 20.7% | 4.5% | 3.5% | −23.2% | 13.0% | 8.2% | 7.1% | −142.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CCEL's financial statements (latest annual report filed February 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CCEL financial results
In fiscal year 2025 (ended November 30, 2025), Cryo-Cell International reported revenue of $31.6 million, down 1.3% from the year before. It had a net loss of $2.4 million, a net profit margin of −7.7%. Diluted earnings per share came to −$0.27. Over five years revenue grew at an average rate of 0.3% a year.
See the CCEL stock overview for the latest quote and news, or the CCEL chart for price history and technical indicators.
CCEL income statement FAQ
What is Cryo-Cell International's annual revenue?
Cryo-Cell International reported total revenue of $31.6 million for fiscal year 2025, which ended on November 30, 2025. That was down 1.3% from $32.0 million the previous year.
Is Cryo-Cell International profitable?
No. Cryo-Cell International reported a net loss of $2.4 million in fiscal 2025, a net profit margin of −7.7%; its operating margin was 15.3%.
What is Cryo-Cell International's gross margin?
Cryo-Cell International's gross margin was 76.6% in fiscal 2025: for every $100 of revenue, Cryo-Cell International kept $77 after the direct cost of its products and services.
How much does Cryo-Cell International spend on research and development?
Cryo-Cell International spent $0.4 million on research and development in fiscal 2025, 1.2% of revenue.
How fast is Cryo-Cell International growing?
Revenue grew 0.3% a year on average over the last five fiscal years, from $31.1 million to $31.6 million.
What are Cryo-Cell International's earnings per share?
Cryo-Cell International earned $-0.27 per diluted share in fiscal 2025, compared with $0.08 a year earlier.
When does Cryo-Cell International's fiscal year end?
Cryo-Cell International's fiscal year ends in November. The latest annual report covers the year ended November 30, 2025 and was filed on February 27, 2026.